Cardiome announces settlement of debt and termination of line of credit with
VANCOUVER, March 4, 2013
VANCOUVER, March 4, 2013 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME /
TSX: COM) today announced it has made the final payment to Merck, known as MSD
outside the United States and Canada, of $13 million (currency in U.S.
dollars) which has been accepted by Merck as full and final settlement of all
amounts owing under the line of credit stemming from the companies'
collaboration and license agreement for vernakalant, signed in April 2009.
Under the terms of the December 10, 2012, settlement agreement between the
companies, upon payment of $20 million by Cardiome to Merck on or before March
31, 2013, Cardiome's outstanding debt of $50 million owed to Merck would be
settled. Previously, Cardiome made an initial payment of $7 million to Merck.
Today's final payment of $13 million concludes Cardiome's total payment of $20
million to Merck and consequently terminates the credit facility and releases
and discharges the collateral security Merck had taken in respect of the
advances under the line of credit.
As part of the settlement agreement, Cardiome shall purchase, in the amount of
an additional $3 million, and take delivery of, vernakalant IV finished goods
inventory and IV and oral active pharmaceutical ingredient (API). Cardiome
expects the IV materials would support ongoing commercialization of BRINAVESS™
(vernakalant intravenous or IV). Vernakalant oral API is expected to be
sufficient to support potential clinical trials that may be conducted in the
"I am pleased by the progress we are making as we execute the multi-step
process to transfer vernakalant back to Cardiome," stated William Hunter,
M.D., interim CEO of Cardiome. "In the coming months we will be establishing a
small, direct Cardiome sales force to promote BRINAVESS^TM product sales in
Europe and we will begin planning our regulatory strategy to further develop
both intravenous and oral vernakalant in order to achieve its maximum
potential in the treatment of atrial fibrillation."
Vernakalant IV is marketed under the brand name BRINAVESS™ and is approved in
the European Union and certain other markets worldwide for the rapid
conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults:
for non-surgery patients with AF of seven days or less and for post-cardiac
surgery patients with AF of three days or less. Vernakalant IV is not
approved for use in the United States or Canada.
About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a biopharmaceutical company dedicated to the
discovery, development and commercialization of new therapies that will
improve the health of patients around the world. Cardiome has one marketed
product, BRINAVESS^TM (vernakalant IV), approved in Europe and other
territories for the rapid conversion of recent onset atrial fibrillation to
sinus rhythm in adults.
Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock
Exchange (COM). For more information, please visit our web site at
Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 or
forward-looking information under applicable Canadian securities legislation
that may not be based on historical fact, including without limitation
statements containing the words "believe", "may", "plan", "will", "estimate",
"continue", "anticipate", "intend", "expect" and similar expressions.
Forward- looking statements may involve, but are not limited to, comments with
respect to our objectives and priorities for the remainder of 2013 and beyond,
our strategies or future actions, our targets, expectations for our financial
condition and the results of, or outlook for, our operations, research and
development and product and drug development. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors that may
cause the actual results, events or developments to be materially different
from any future results, events or developments expressed or implied by such
forward-looking statements. Many such known risks, uncertainties and other
factors are taken into account as part of our assumptions underlying these
forward-looking statements and include, among others, the following: general
economic and business conditions in the United States, Canada, Europe, and the
other regions in which we operate; market demand; technological changes that
could impact our existing products or our ability to develop and commercialize
future products; competition; existing governmental legislation and
regulations and changes in, or the failure to comply with, governmental
legislation and regulations; availability of financial reimbursement coverage
from governmental and third-party payers for products and related treatments;
adverse results or unexpected delays in pre-clinical and clinical product
development processes; adverse findings related to the safety and/or efficacy
of our products or products; decisions, and the timing of decisions, made by
health regulatory agencies regarding approval of our technology and products;
the requirement for substantial funding to expand commercialization
activities; and any other factors that may affect our performance. In
addition, our business is subject to certain operating risks that may cause
any results expressed or implied by the forward-looking statements in this
presentation to differ materially from our actual results. These operating
risks include: our ability to attract and retain qualified personnel; our
ability to successfully complete pre-clinical and clinical development of our
products; changes in our business strategy or development plans; intellectual
property matters, including the unenforceability or loss of patent protection
resulting from third-party challenges to our patents; market acceptance of our
technology and products; our ability to successfully manufacture, market and
sell our products; the availability of capital to finance our activities; and
any other factors described in detail in our filings with the Securities and
Exchange Commission available at www.sec.gov and the Canadian securities
regulatory authorities at www.sedar.com. Given these risks, uncertainties and
factors, you are cautioned not to place undue reliance on such forward-looking
statements and information, which are qualified in their entirety by this
cautionary statement. All forward-looking statements and information made
herein are based on our current expectations and we undertake no obligation to
revise or update such forward-looking statements and information to reflect
subsequent events or circumstances, except as required by law.
SOURCE Cardiome Pharma Corp.
Cardiome Investor Relations
(604) 676-6993 or Toll Free: 1-800-330-9928
Press spacebar to pause and continue. Press esc to stop.